The Indiana University Melvin and Bren Simon Cancer Center is a matrix Cancer Center that organizes and facilitates cancer research, education, patient care, and cancer control and prevention. The Mission of the Indiana University Melvin and Bren Simon Cancer Center is to decrease the mortality and suffering from cancer by conducting outstanding translational research, by providing excellence in education, and by delivering high quality patient-centered care. This application seeks funds for the Center's five research programs, seven shared facilities. Clinical Protocol and Data Management, Protocol Review and Monitoring System, Early Phase Clinical Research Support, and Data Safety and Monitoring. In addition, funds are requested for Administration, Planning and Evaluation, Developmental Funds, and Senior Leaders. The research programs have been organized and developed to be highly interactive, allowing for successful collaboration among basic, clinical, and population science researchers. The research programs are: 1) Breast Cancer, 2) Cancer Prevention and Control, 3) Experimental and Developmental Therapeutics, 4) Hematopoiesis, Microenvironment and Immunology, 5) Tumor Microenvironment and Metastasis. Supporting the members of these programs are seven shared resources. Preclinical share resources: 1) Chemical Genomics, 2) Flow Cytometry,3) In Vivo Therapeutics. Clinical shared resources: 1) Clinical Pharmacology and Analytical Core, 2) Tissue Procurement and Distribution. Other shared resource: Biostatistics and Data Management

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
2P30CA082709-15
Application #
8742219
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Kedage, Vivekananda; Selvaraj, Nagarathinam; Nicholas, Taylor R et al. (2016) An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. Cell Rep 17:1289-1301
Nudelman, Kelly N H; McDonald, Brenna C; Wang, Yang et al. (2016) Cerebral Perfusion and Gray Matter Changes Associated With Chemotherapy-Induced Peripheral Neuropathy. J Clin Oncol 34:677-83
Hoggatt, Jonathan; Hoggatt, Amber F; Tate, Tiffany A et al. (2016) Bleeding the laboratory mouse: Not all methods are equal. Exp Hematol 44:132-137.e1
Haley, James; Tomar, Sunil; Pulliam, Nicholas et al. (2016) Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget 7:32810-20
Radovich, Milan; Solzak, Jeffrey P; Hancock, Bradley A et al. (2016) A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer 114:477-84
Li, Wei; Liu, Liangyi; Gomez, Aurelie et al. (2016) Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight 1:
Champion, Victoria L; Rawl, Susan M; Bourff, Sara A et al. (2016) Randomized trial of DVD, telephone, and usual care for increasing mammography adherence. J Health Psychol 21:916-26
Meijome, Tomas E; Baughman, Jenna T; Hooker, R Adam et al. (2016) C-Mpl Is Expressed on Osteoblasts and Osteoclasts and Is Important in Regulating Skeletal Homeostasis. J Cell Biochem 117:959-69
Richine, B M; Virts, E L; Bowling, J D et al. (2016) Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia. Leukemia 30:2094-2097
Masters, Andrea R; Gufford, Brandon T; Lu, Jessica Bo Li et al. (2016) Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. J Pharmacol Exp Ther 358:230-8

Showing the most recent 10 out of 220 publications